KR101287919B1 - 약학적 조성물 - Google Patents

약학적 조성물 Download PDF

Info

Publication number
KR101287919B1
KR101287919B1 KR1020067024763A KR20067024763A KR101287919B1 KR 101287919 B1 KR101287919 B1 KR 101287919B1 KR 1020067024763 A KR1020067024763 A KR 1020067024763A KR 20067024763 A KR20067024763 A KR 20067024763A KR 101287919 B1 KR101287919 B1 KR 101287919B1
Authority
KR
South Korea
Prior art keywords
glycopyrrolate
formulation
delete delete
powder
magnesium stearate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067024763A
Other languages
English (en)
Korean (ko)
Other versions
KR20070033978A (ko
Inventor
데이비드 모르톤
마틴 쇼트
레베카 데이비스
Original Assignee
벡투라 그룹 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32408337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101287919(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 벡투라 그룹 피엘씨 filed Critical 벡투라 그룹 피엘씨
Publication of KR20070033978A publication Critical patent/KR20070033978A/ko
Application granted granted Critical
Publication of KR101287919B1 publication Critical patent/KR101287919B1/ko
Assigned to 벡투라 리미티드 reassignment 벡투라 리미티드 권리의 전부이전등록 Assignors: 벡투라 그룹 피엘씨
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020067024763A 2004-04-30 2005-04-29 약학적 조성물 Expired - Lifetime KR101287919B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0409703.6A GB0409703D0 (en) 2004-04-30 2004-04-30 Pharmaceutical compositions
GB0409703.6 2004-04-30
PCT/EP2005/051980 WO2005105043A2 (en) 2004-04-30 2005-04-29 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
KR20070033978A KR20070033978A (ko) 2007-03-27
KR101287919B1 true KR101287919B1 (ko) 2013-07-18

Family

ID=32408337

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067024763A Expired - Lifetime KR101287919B1 (ko) 2004-04-30 2005-04-29 약학적 조성물

Country Status (26)

Country Link
US (1) US20080063719A1 (cg-RX-API-DMAC7.html)
EP (3) EP1755555B1 (cg-RX-API-DMAC7.html)
JP (2) JP5000483B2 (cg-RX-API-DMAC7.html)
KR (1) KR101287919B1 (cg-RX-API-DMAC7.html)
CN (3) CN107252423A (cg-RX-API-DMAC7.html)
AU (2) AU2005237266B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0510500B8 (cg-RX-API-DMAC7.html)
CA (1) CA2563760C (cg-RX-API-DMAC7.html)
CY (6) CY1113069T1 (cg-RX-API-DMAC7.html)
DK (2) DK2422766T3 (cg-RX-API-DMAC7.html)
ES (2) ES2388289T3 (cg-RX-API-DMAC7.html)
GB (1) GB0409703D0 (cg-RX-API-DMAC7.html)
HU (4) HUE025463T2 (cg-RX-API-DMAC7.html)
IL (2) IL178651A (cg-RX-API-DMAC7.html)
LT (1) LTC2422766I2 (cg-RX-API-DMAC7.html)
LU (2) LU92176I2 (cg-RX-API-DMAC7.html)
MX (2) MXPA06012493A (cg-RX-API-DMAC7.html)
NO (1) NO20065502L (cg-RX-API-DMAC7.html)
NZ (1) NZ550479A (cg-RX-API-DMAC7.html)
PL (2) PL1755555T3 (cg-RX-API-DMAC7.html)
PT (2) PT1755555E (cg-RX-API-DMAC7.html)
RU (1) RU2396943C2 (cg-RX-API-DMAC7.html)
SG (3) SG186673A1 (cg-RX-API-DMAC7.html)
SI (2) SI1755555T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005105043A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200609350B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200078162A (ko) 2018-12-21 2020-07-01 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
US20100247658A1 (en) * 2007-12-13 2010-09-30 Gerhard Muhrer Organic compounds
WO2009074666A1 (en) * 2007-12-13 2009-06-18 Novartis Ag Organic compounds
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
MX2011011123A (es) * 2009-04-24 2011-11-04 Schering Corp Formulaciones de aglomerado utiles en inhaladores de polvo seco.
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB0921481D0 (en) * 2009-12-08 2010-01-20 Vectura Ltd Process and product
EP2552414A4 (en) * 2010-03-31 2014-05-14 Glenmark Pharmaceuticals Ltd PHARMACEUTICAL POWDER COMPOSITION FOR INHALATION
WO2011120779A1 (en) 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
RU2580312C2 (ru) * 2010-04-21 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения частиц с пониженным электростатическим зарядом
US20130157991A1 (en) 2010-08-31 2013-06-20 Osama Ahmed Aswania Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same
ES2705494T3 (es) 2010-08-31 2019-03-25 Glaxosmithkline Ip Dev Ltd Productos farmacológicos para la inhalación de polvo seco que presentan propiedades de control de la humedad y procedimientos de administración de los mismos
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
NZ710740A (en) 2013-02-28 2020-06-26 Dermira Inc Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
JP6454323B2 (ja) † 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
HRP20260435T1 (hr) * 2014-09-09 2026-05-08 Vectura Limited Formulacija koja sadrži glikopirolat, postupak i uređaj
BR112017007587A2 (pt) * 2014-10-16 2018-01-30 Teva Branded Pharmaceutical Products R&D Inc processo para preparar uma formulação farmacêutica em pó seca e inalável
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10617674B2 (en) 2016-03-08 2020-04-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
WO2017153702A1 (en) 2016-03-08 2017-09-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
ES2805434T3 (es) 2016-07-29 2021-02-12 Inke Sa Procedimiento de estabilización de tamaño de partícula
JP6781829B2 (ja) 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
EP3595631B1 (en) * 2017-03-15 2024-11-27 Vectura Limited Method and formulation
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
HUE054266T2 (hu) 2017-12-11 2021-08-30 Mereo Biopharma 1 Ltd 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid alkalmazása krónikus obstruktív tüdõbetegség akut megjelenésének megelõzésében
KR102899004B1 (ko) 2017-12-11 2025-12-12 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도
US20250050042A1 (en) 2021-12-21 2025-02-13 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002529498A (ja) 1998-11-13 2002-09-10 ヤゴ・リサーチ・アクチェンゲゼルシャフト 吸入用の乾燥粉末
US20040037785A1 (en) 2000-11-30 2004-02-26 Staniforth John Nicholas Method of making particles for use in a pharmaceutical composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3709039A (en) * 1970-08-31 1973-01-09 Gen Time Corp Comfort humidity indicator
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
ES2292598T3 (es) 2000-06-27 2008-03-16 Vectura Limited Metodo para producir particulas para usar en una composicion farmaceutica.
NZ526059A (en) * 2000-11-30 2005-05-27 Vectura Ltd Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition
CN100496608C (zh) * 2001-03-30 2009-06-10 洁垢技术有限公司 药用气溶胶制剂
EP1501479A1 (en) * 2002-05-07 2005-02-02 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
GB2405798A (en) * 2003-09-15 2005-03-16 Vectura Ltd Dry powder inhaler with primary and secondary piercing elements and a medicament pack for use with an inhalation device.
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
WO2006100453A1 (en) * 2005-03-24 2006-09-28 Sosei R & D Ltd. Glycopyrronium salts and their therapeutic use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002529498A (ja) 1998-11-13 2002-09-10 ヤゴ・リサーチ・アクチェンゲゼルシャフト 吸入用の乾燥粉末
US20040037785A1 (en) 2000-11-30 2004-02-26 Staniforth John Nicholas Method of making particles for use in a pharmaceutical composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200078162A (ko) 2018-12-21 2020-07-01 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법

Also Published As

Publication number Publication date
SI2422766T1 (sl) 2015-10-30
CY1116655T1 (el) 2017-03-15
PL1755555T3 (pl) 2012-11-30
PT1755555E (pt) 2012-08-17
NO20065502L (no) 2007-01-24
AU2011200543A8 (en) 2011-03-31
IL223545A0 (en) 2013-02-03
JP2012031209A (ja) 2012-02-16
LU92392I2 (fr) 2015-11-02
CY2015059I1 (el) 2020-05-29
HUS1300006I1 (hu) 2016-07-28
ZA200609350B (en) 2008-04-30
RU2396943C2 (ru) 2010-08-20
LTC2422766I2 (lt) 2020-02-10
CN102008453A (zh) 2011-04-13
CN1964700A (zh) 2007-05-16
ES2546982T3 (es) 2015-09-30
EP1755555B1 (en) 2012-05-23
WO2005105043A3 (en) 2006-05-04
CN107252423A (zh) 2017-10-17
MXPA06012493A (es) 2007-01-29
AU2005237266B2 (en) 2010-11-11
EP2422766A3 (en) 2012-04-25
EP1755555A2 (en) 2007-02-28
LU92176I2 (fr) 2013-05-27
SG10201605001SA (en) 2016-08-30
PT2422766E (pt) 2015-10-12
SG186673A1 (en) 2013-01-30
CY2013012I1 (el) 2015-08-05
HK1095282A1 (en) 2007-05-04
ES2388289T3 (es) 2012-10-11
AU2011200543A1 (en) 2011-03-03
NZ550479A (en) 2009-11-27
BRPI0510500B1 (pt) 2019-04-24
AU2011200543B2 (en) 2012-11-29
SI1755555T1 (sl) 2012-10-30
CY1113069T1 (el) 2015-08-05
IL223545A (en) 2016-04-21
JP5124718B2 (ja) 2013-01-23
RU2006142322A (ru) 2008-06-20
CY2015060I1 (el) 2020-05-29
HK1167334A1 (en) 2012-11-30
BRPI0510500A (pt) 2007-10-30
US20080063719A1 (en) 2008-03-13
EP2422767A2 (en) 2012-02-29
EP2422766B1 (en) 2015-06-24
JP2007535522A (ja) 2007-12-06
PL2422766T3 (pl) 2015-11-30
HUS1500073I1 (hu) 2016-02-29
CY2014015I1 (el) 2015-12-09
WO2005105043A2 (en) 2005-11-10
MX341426B (es) 2016-08-18
EP2422766A2 (en) 2012-02-29
SG152292A1 (en) 2009-05-29
LU92176I9 (cg-RX-API-DMAC7.html) 2019-01-04
CY2014015I2 (el) 2015-12-09
GB0409703D0 (en) 2004-06-02
KR20070033978A (ko) 2007-03-27
CA2563760A1 (en) 2005-11-10
CA2563760C (en) 2013-07-02
CY2013012I2 (el) 2015-08-05
AU2005237266A1 (en) 2005-11-10
HUS1500072I1 (hu) 2016-02-29
HUE025463T2 (en) 2016-02-29
EP2422767A3 (en) 2012-04-25
BRPI0510500B8 (pt) 2021-05-25
DK1755555T3 (da) 2012-08-20
JP5000483B2 (ja) 2012-08-15
IL178651A0 (en) 2007-02-11
IL178651A (en) 2012-12-31
DK2422766T3 (da) 2015-08-31

Similar Documents

Publication Publication Date Title
EP1755555B1 (en) Methods for preparing dry powder compositions of glycopyrrolate
ES2587135T3 (es) Procedimiento de fabricación de partículas para su uso en una composición farmacéutica
CN103501781B (zh) 吡咯糖用于治疗心动过速的用途
MXPA06006238A (es) Un producto medico que comprende un tiotropio en un contenedor a prueba de humedad.
AU2015314272B2 (en) Formulation comprising glycopyrrolate, method and apparatus
CN107106514A (zh) 干燥粉末配制剂
HK1095282B (en) Methods for preparing dry powder compositions of glycopyrrolate
HK1167334B (en) Dry powder compositions of glycopyrrolate and magnesium stearate
HK1168273A (en) Methods for preparing dry powder compositions of glycopyrrolate
HK40035236A (en) Formulation comprising glycopyrrolate, method and apparatus
HK1241279B (en) Formulation comprising glycopyrrolate, method and apparatus
HK1241279A1 (en) Formulation comprising glycopyrrolate, method and apparatus

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

FPAY Annual fee payment

Payment date: 20160630

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20170630

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PC1801 Expiration of term

St.27 status event code: N-4-6-H10-H14-oth-PC1801

Not in force date: 20250430

Ip right cessation event data comment text: Termination Category : EXPIRATION_OF_DURATION